Journal Articles

Donald and Barbara Zucker School of Medicine
Academic Works

2015

Cardiovascular and cerebrovascular risk factors and
events associated with second-generation
antipsychotic compared to antidepressant use in a
non-elderly adult sample: results from a claimsbased inception cohort study
C. U. Correll
Hofstra Northwell School of Medicine

B. I. Joffe
L. M. Rosen
Northwell Health

T. B. Sullivan
Northwell Health

R. T. Joffe
Hofstra Northwell School of Medicine

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Psychiatry Commons
Recommended Citation
Correll CU, Joffe B, Rosen LM, Sullivan T, Joffe RT. Cardiovascular and cerebrovascular risk factors and events associated with secondgeneration antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort
study. . 2015 Jan 01; 14(1):Article 813 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/813. Free full text
article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works.

RESEARCH REPORT

Cardiovascular and cerebrovascular risk factors
and events associated with second-generation
antipsychotic compared to antidepressant use in a
non-elderly adult sample: results from a claims-based
inception cohort study
CHRISTOPH U. CORRELL1-4, BENJAMIN I. JOFFE5, LISA M. ROSEN3, TIMOTHY B. SULLIVAN4,6, RUSSELL T. JOFFE2,4,7
1
Zucker Hillside Hospital, Psychiatry Research, North Shore - Long Island Jewish Health System, Glen Oaks, New York, NY, USA; 2Hofstra North Shore - Long
Island Jewish School of Medicine, Hempstead, New York, NY, USA; 3Feinstein Institute for Medical Research, Manhasset, New York, NY, USA; 4Long Island Jewish - North Shore Staten Island University Hospital, Staten Island, New York, NY, USA; 5Columbia College, Columbia University, New York, NY, USA; 6New York
Medical College, Valhalla, NY, USA; 7Boston University School of Medicine, Boston, MA, USA

This is a study of the metabolic and distal cardiovascular/cerebrovascular outcomes associated with the use of second-generation antipsychotics
(SGAs) compared to antidepressants (ADs) in adults aged 18-65 years, based on data from Thomson Reuters MarketScanV Research Databases
2006-2010, a commercial U.S. claims database. Interventions included clinicians’ choice treatment with SGAs (allowing any comedications)
versus ADs (not allowing SGAs). The primary outcomes of interest were time to inpatient or outpatient claims for the following diagnoses within one year of SGA or AD discontinuation: hypertension, ischemic and hypertensive heart disease, cerebrovascular disease, diabetes mellitus,
hyperlipidemia, and obesity. Secondary outcomes included the same diagnoses at last follow-up time point, i.e., not censoring observations at
365 days after SGA or AD discontinuation. Cox regression models, adjusted for age, gender, diagnosis of schizophrenia and mood disorders,
and number of medical comorbidities, were run. Among 284,234 individuals, those within one year of exposure to SGAs versus ADs showed a
higher risk of essential hypertension (adjusted hazard ratio, AHR51.16, 95% CI: 1.12-1.21, p<0.0001), diabetes mellitus (AHR51.43, CI: 1.331.53, p<0.0001), hypertensive heart disease (AHR51.34, CI: 1.10-1.63, p<0.01), stroke (AHR51.46, CI: 1.22-1.75, p<0.0001), coronary artery
disease (AHR51.17, CI: 1.05-1.30, p<0.01), and hyperlipidemia (AHR51.12, CI: 1.07-1.17, p<0.0001). Unrestricted follow-up results were consistent with within one-year post-exposure results. Increased risk for stroke with SGAs has previously only been demonstrated in elderly
patients, usually with dementia. This study documents, for the first time, a significantly increased risk for stroke and coronary artery disease in a
non-elderly adult sample with SGA use. We also confirm a significant risk for adverse metabolic outcomes. These findings raise concerns about
the longer-term safety of SGAs, given their widespread and chronic use.
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Second-generation antipsychotics (SGAs) were introduced
approximately 20 years ago as supposedly safer and bettertolerated alternatives to first-generation antipsychotics for
the treatment of schizophrenia and related disorders (1-3).
They have proven to be effective for schizophrenia (4,5),
but their use has extended to major mood disorders (6,7)
and a broad range of other psychiatric illness (8,9).
The initial optimism about safety was refuted by the welldocumented adverse metabolic effects of these drugs (1013). U.S. Food and Drug Administration (FDA)’s warnings
about severe metabolic side effects were followed by the
establishment of guidelines for cardiometabolic monitoring
in patients prescribed antipsychotics (14). Clinically relevant, unfavorable cardiometabolic effects, including obesity, diabetes mellitus, hypertension, and abnormal blood
lipids, were commonly reported across the lifespan, from
children and adolescents to the elderly (10,15-18).
However, despite well-documented proximal cardiometabolic side effects that are established risk factors for future
cardiovascular and cerebrovascular events, data on the potential adverse cardiovascular and cerebrovascular consequences of SGA use are scarce and, even for high-metabolic
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risk agents, contradictory (19). Limited and often inconclusive documentation of such adverse events has largely been
confined to studies of the elderly, who are closer to experiencing such events but also have a high medicationindependent risk profile for myocardial infarction and
stroke (20-38).
As the majority of patients receiving SGAs are younger
adults, and even children and adolescents (39), we sought
to examine the potential detrimental metabolic, cardiovascular, and cerebrovascular effects in a non-elderly adult
population. Given that these adverse consequences are very
clinically significant but relatively uncommon and require
longer-term follow-up, we studied a large sample using a
healthcare claims database.

METHODS
Database
We obtained the study data from the Thomson Reuters
MarketScanV Research Databases, a commercial U.S. claims
R
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database, for years 2006-2010. This database contains individual-level, de-identified, healthcare claims information
from employers, health plans, hospitals, Medicare, and Medicaid programs. Data for individual patients are integrated
from all providers of care, maintaining all healthcare utilization and cost record connections at the patient level.
Patients were excluded from the database for the following reasons: a) no enrollment in 2006; b) enrolled in a health
plan that did not capture medication claims nor mental
health and substance abuse claims; c) unavailable person
level enrollment data, making it impossible to differentiate
patients from other enrollees, as well as identify subjects
with no claims data; d) age <18 or >65, as the primary sample of interest was non-elderly adults; e) claims in 2006 for
any of the medical diagnoses used as outcomes; f) claims for
any of the medical diagnoses used as outcomes prior to first
observed SGA exposure or antidepressant (AD) treatment;
g) follow-up <6 months in 2007-2010; and h) no exposure
to SGA or AD treatment in 2007-2010.
The start date for the study was defined as the first exposure to SGA or AD in 2007-2010. The rationale for choosing
a minimum of 6-month follow-up from the start date was
to allow sufficient time for an outcome of interest to be observed after starting SGAs or ADs. The study end date was
defined as a subject’s last known date of enrollment in a
health plan that captured drug and mental health claims or
365 days after the last exposure to SGA or AD. Subjects were
followed through their study end, which allowed different
event types to be observed within a subject.
Subjects not enrolled consecutively in a health plan during a year were assumed to have been enrolled for all months
prior to their final month of enrollment. Any month skipped
between the first and last month of enrollment was assumed
to be either an error or that having an outcome of interest
during that month was unlikely. Subjects not enrolled in a
drug prescription or mental health/substance abuse claims
program for consecutive years had their end date defined to
be the last date of enrollment in a health plan that captured
both drug claims and mental health/substance abuse claims.
These observations were censored because we did not know
if any outcomes of interest occurred during these periods.
Subjects with this pattern of sporadic enrollment in a health
plan that captures drug and mental health or substance
abuse claims accounted for <1% of the entire sample.

SGA inception cohort
The SGA inception cohort included subjects aged 18-65
years without SGA use and without medical diagnosis claim
of any of the outcomes of interest in 2006, i.e., within 12
months prior to the study period (2007-2010), or any point
prior to the start of SGAs, and initiating continuous SGA
treatment for at least 4 weeks during 2007-2010.
Continuous use was defined as no more than 1 week without use of an SGA (i.e., not having an SGA prescription

refilled when the supply of the previous prescription runs
out). This assumption was based on the last prescription fill
date and the days’ supply, which was used to calculate when a
prescription should have been refilled. Medication claims for
a SGA supply <1 week or >180 days were excluded, as this
was deemed either an inappropriate trial or clinically implausible. The use of other concurrent medications, including
ADs, was allowed, but not accounted for in this cohort.

Comparison cohort
The comparison cohort included the remaining subjects
aged 18-65 years without SGA use, AD use, or a medical
diagnosis claim of any of the outcomes of interest in 2006,
i.e., within 12 months prior to the study period (2007-2010),
or any point prior to the start of ADs. Additionally, patients
initiated continuous AD treatment for at least 4 weeks during the study period. Medication claims for an AD supply
<1 week or >180 days were excluded. Unlike the SGA
cohort, which may have been exposed to ADs, the AD
cohort was not exposed to SGAs during the entire study
period. The use of other concurrent medications, excluding
SGAs, was allowed, but not accounted for in this cohort.
We chose an AD initiator cohort as the comparison
group in order to balance background risk factors present in
SGA initiators that are based on mental illness and unhealthy lifestyle behaviors, including smoking, which are
related to a higher risk for the studied outcomes, all of which
have been associated with depression and even AD treatment too (40-42). Moreover, using defined initiation time
point in both cohorts allowed us to control for severity of
mental disorder, while having a time point of discontinuation allowed us to use the same rule for right-censoring in
both groups in the primary analysis.

Outcomes
Primary outcomes of interest were times to inpatient and
outpatient claims for the following diagnoses within one
year of treatment discontinuation (ICD-9 codes in parentheses): hypertension (401, 402), ischemic and hypertensive heart disease (410, 413, 414), cerebrovascular disease
(434, 435), diabetes mellitus (250), hyperlipidemia (272),
and obesity (278). Secondary outcomes included the same
diagnoses at last follow-up time point, i.e., not censoring
the observations at 365 days after the last exposure to either
SGAs or ADs, in order to examine the robustness of our
findings and allow for longer-term carry over effects.

Statistical analysis
Cox (proportional hazards) regression analysis, censoring patients without an event of interest at 365 days after
57

Table 1 Sample characteristics

N
Age, years6SD
Males, N (%)

Total

SGA exposed cohort

AD exposed cohort

284,234

31,207

253,027

p

44.46610.74

44.91611.16

44.40610.69

<0.0001
<0.0001

83,606 (29.41)

10,224 (32.76)

73,382 (29.00)

Number of medical disorders at baseline, median (Q1, Q3)

5.00 (2.00, 9.00)

7.00 (3.00, 12.00)

5.00 (2.00, 9.00)

Patient years of follow-up censoring patients 365 days after
treatment discontinuation, median (Q1, Q3)

1.49 (1.00, 2.62)

1.55 (1.00, 2.87)

1.48 (1.00, 2.59)

<0.0001

Patient years of follow-up not censoring patients 365 days
after treatment discontinuation, median (Q1, Q3)

2.55 (1.62, 3.36)

2.63 (1.62, 3.55)

2.54 (1.62, 3.34)

0.0001

Patient days of treatment exposure, median (Q1, Q3)

180 (60, 480)

150 (60, 420)

180 (60, 480)

<0.0001

Mood disorders diagnosis, N (%)

60,906 (21.43)

22,681 (72.68)

38,225 (15.11)

<0.0001

Schizophrenia diagnosis, N (%)

2,027 (0.71)

1,842 (5.90)

185 (0.07)

<0.0001

SGAs prescribed during the study, N (%)
Aripiprazole

7,316 (2.57)

Asenapine

8 (0.00)

Clozapine

60 (0.02)

Olanzapine

2,901 (1.02)

Quetiapine

12,094 (4.25)

Risperidone

3,362 (1.18)

Ziprasidone

1,469 (0.52)

Mixed SGA group (see text)

3,997 (1.41)

SGA – second-generation antipsychotic, AD – antidepressant, Q1 – quartile 1, Q3 – quartile 3

last exposure to the studied medication or last date of health
plan enrollment, was used to separately model each outcome of interest as a function of exposure group (i.e., SGA
versus AD). The proportional hazards assumption was evaluated by plotting the log negative log of the survival function
by the log of time.
Adverse outcomes that were significantly associated with
SGA exposure in the univariable Cox regression analysis
were further explored using multivariable Cox regression
analysis. The multivariable models included treatment group,
age, gender, diagnosis of schizophrenia, diagnosis of mood
disorder, and a medical morbidity count. Schizophrenia
and mood disorders were identified by inpatient and outpatient claims. The medical morbidity count was generated
by summing the number of unique medical diagnoses recorded for each subject in 2006, which was used as a covariate in order to adjust for potential differences between the
SGA and AD groups regarding overall medical morbidity,
(related) lifestyle behaviors, and/or medical service utilization that could increase the risk for the studied outcomes.
By definition, medical comorbidities excluded those used
as outcomes, as patients had to be without these diagnoses
in 2006 and prior to starting SGAs or ADs.
The above analyses were repeated without censoring subjects 365 days after their last SGA or AD exposure, respectively. In these analyses, the study end was redefined to be
the date the respective outcome of interest occurred or the
last date of enrollment in a health plan. Again, subjects were
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only censored for the specific outcome of interest that occurred, being followed for all other outcomes that had not
occurred until last date of enrollment in a health plan.
Since individual SGAs differ regarding their short- and
medium-term cardiometabolic adverse effect profile (11,13,
15,17,18), we also performed subgroup analyses to evaluate
the intermediate metabolic and distal cardiovascular and
cerebrovascular risks of the five most frequently used SGAs,
i.e., aripiprazole, olanzapine, quetiapine, risperidone, and
ziprasidone. Unfortunately, the clozapine and asenapine
groups were too small to perform reliable analyses. Whenever more than one SGA was used, a subject was classified
based on the SGA that was received for the majority of the
study period (i.e., more than two-thirds of a subject’s “exposure” to a specific SGA). If no single SGA was received
for >67% of the study period, a subject was classified as
belonging to the “mixed SGA” group.

RESULTS
The sample (N5284,234) included 83,606 men and
200,628 women, with a mean age of 44.46610.74 years.
Details of the sample are provided in Table 1.
In univariable Cox regression analyses, SGA exposure
was associated with a significantly increased risk for all the
outcomes of interest (Table 2). In addition to the well-established proximal metabolic risks of SGAs, such as essential
World Psychiatry 14:1 - February 2015

Table 2 Univariable metabolic and cardiovascular risk associated

with SGA exposure at one year
Hazard ratio
(95% CI) for SGA users
vs. AD users

Chi square

p

Essential hypertension

1.27 (1.23-1.31)

208.1066

<0.0001

Diabetes mellitus

1.73 (1.63-1.83)

335.1633

<0.0001

Obesity

1.24 (1.18-1.32)

56.1796

<0.0001

Outcome: claims diagnosis

Stroke

2.12 (1.83-2.45)

99.5837

<0.0001

Hypertensive heart disease

1.56 (1.33-1.84)

28.9700

<0.0001

Myocardial infarction

1.40 (1.13-1.72)

9.8147

0.0017

Angina

1.32 (1.15-1.51)

15.4601

<0.0001

Coronary artery disease

1.52 (1.39-1.67)

82.8166

<0.0001

Transient ischemic attack

1.70 (1.48-1.95)

57.3919

<0.0001

Hyperlipidemia

1.28 (1.24-1.33)

175.9416

<0.0001

SGA – second-generation antipsychotic, AD – antidepressant

hypertension, diabetes mellitus, obesity, and hyperlipidemia,
there was a significantly increased risk for myocardial
infarction (hazard ratio, HR51.40, CI: 1.13-1.72), stroke
(HR52.12, CI: 1.83-2.45), angina (HR51.32, CI: 1.15-1.51),
hypertensive heart disease (HR51.56, CI: 1.33-1.84), coronary artery disease (HR51.52, CI: 1.39-1.67), and transient
ischemic attack (HR51.70, CI: 1.48-1.95).
In multivariable Cox regression analyses, adjusting for
gender, age, schizophrenia, mood disorders, and medical
morbidity count, the risk for stroke, hypertensive heart disease and coronary heart disease remained significantly higher
in the SGA exposure group (Table 3).
Table 4 presents univariable and multivariable Cox regression analyses for outcomes of interest when participants
were not censored at one year, serving as a sensitivity analysis for our primary analyses of outcomes at one year after
SGA or AD discontinuation. The univariable analyses were

consistent with the results within one year of discontinuation.
The multivariable results for the uncensored data (Table 4)
were also consistent with the primary results restricting
follow-up to 365 days post exposure (Table 3).
Results from the multivariable analyses comparing AD
users with clinicians’ choice SGA treatment groups are
shown in Table 5. Individual antipsychotic groups differed
considerably in size, resulting in differences in power to
detect significant differences in outcomes compared to AD
users. Even despite this confound, patients exposed to olanzapine, quetiapine and mixed antipsychotic use had a higher
number of adverse metabolic and cardiovascular outcomes
(i.e., 6, 8 and 7 out of the ten examined outcomes) compared
to risperidone, aripiprazole and ziprasidone (i.e., 2, 4 and 5
out of ten examined outcomes) (Table 5).
In addition to the risk data presented, the actual incidence
rates per 1000 person-years for the outcomes of interest are
presented in Table 6.

DISCUSSION
We used a commercial claims database with broad coverage of health insured non-elderly adults in the U.S. to examine the risks associated with SGA use compared to AD use
within one year of exposure and without restriction of followup after discontinuation during a 4-year period, 2007-2010.
Despite exclusion of the elderly, we observed a statistically
and clinically significant increased risk with SGA use vs. AD
use for proximal cardiometabolic risk factors and outcomes,
such as essential hypertension, dyslipidemia, and diabetes
mellitus, confirming prior reports (10-16). However, importantly, we also observed an increased risk for distal and generally difficult-to-study cardiovascular (i.e., coronary artery
disease) and cerebrovascular (i.e., stroke) outcomes, both
with and without restriction of the follow-up period after

Table 3 Multivariable Cox hazard ratios for significant adverse outcomes of interest at one year

Outcome: claims
diagnosis

Hazard ratio
(95% CI) for SGA
users vs. AD usersa

Hazard ratio
(95% CI) for age
(10 year increments)

Hazard ratio
(95% CI) for gender
(male vs. female)

Hazard ratio
(95% CI) for medical
morbidity count

Essential hypertension

1.16 (1.12-1.21)***

1.60 (1.59-1.62)***

1.35 (1.32-1.39)***

1.01 (1.01-1.01)***

0.98 (0.95-1.01)

1.24 (1.12-1.38)***

Diabetes mellitus

1.43 (1.33-1.53)***

1.53 (1.49-1.56)***

1.20 (1.14-1.26)***

1.00 (1.00–1.01)***

1.12 (1.06-1.19)***

1.74 (1.48-2.04)***

Obesity

0.96 (0.89-1.02)

0.92 (0.91-0.94)***

0.56 (0.52-0.58)***

1.01 (1.00–1.01)***

1.51 (1.44-1.58)***

1.46 (1.24-1.72)***

Stroke

1.46 (1.22-1.75)***

1.71 (1.60-1.82)***

1.21 (1.06-1.39)**

1.04 (1.03-1.05)***

1.25 (1.07-1.45)**

1.43 (0.94-2.18)

Hypertensive heart disease

1.34 (1.10-1.63)**

1.70 (1.60-1.81)***

1.58 (1.39-1.80)***

1.02 (1.01-1.03)***

0.98 (0.84-1.16)

1.37 (0.85-2.20)

Myocardial infarction

1.04 (0.82-1.33)

2.15 (1.98-2.35)***

2.72 (2.33-3.18)***

1.03 (1.02-1.04)***

1.20 (0.99-1.45)

0.81 (0.38-1.75)

Hazard ratio
(95% CI) for
mood disorder

Hazard ratio
(95% CI) for
schizophrenia

Angina

1.03 (0.87-1.21)

1.90 (1.80-2.00)***

1.43 (1.29-1.58)***

1.04 (1.03-1.04)***

1.06 (0.93-1.20)

1.00 (0.63-1.60)

Coronary artery disease

1.17 (1.05-1.30)**

2.24 (2.15-2.32)***

2.24 (2.09-2.40)***

1.03 (1.02-1.03)***

1.06 (0.97-1.16)

1.38 (1.06-1.81)*

Transient ischemic attack

1.17 (0.99-1.38)

1.76 (1.66-1.86)***

1.14 (1.01-1.29)*

1.04 (1.04-1.05)***

1.19 (1.04-1.37)*

1.46 (0.98-2.17)

Hyperlipidemia

1.12 (1.07-1.17)***

1.58 (1.56-1.61)***

1.42 (1.38-1.46)***

1.01 (1.01-1.02)***

1.03 (1.00–1.07)

1.21 (1.08-1.36)**

SGA – second-generation antipsychotic, AD – antidepressant
a
adjusted for gender, age, psychiatric diagnosis and medical morbidity count, *p<0.05, **p<0.01, ***p<0.0001
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Table 4 Univariable and multivariable Cox hazard ratios when

participants are not censored one year after last medication
exposure
Univariable hazard
ratio (95% CI) for SGA
users vs. AD users

Multivariablea hazard
ratio (95% CI) for SGA
users vs. AD users

Essential hypertension

1.29 (1.25-1.33)***

1.18 (1.14-1.22)***

Diabetes mellitus

1.67 (1.59-1.76)***

1.39 (1.30-1.48)***

Obesity

1.25 (1.18-1.31)***

0.94 (0.88-0.99)*

Stroke

2.17 (1.90-2.48)***

1.49 (1.26-1.75)***

Hypertensive heart disease

1.60 (1.38-1.85)***

1.39 (1.17-1.66)**

Myocardial infarction

1.49 (1.19-1.81)**

1.01 (0.79-1.29)

Outcome: claims
diagnosis

Angina

1.34 (1.19-1.51)***

1.05 (0.91-1.21)

Coronary artery disease

1.54 (1.42-1.67)***

1.18 (1.07-1.31)**

Transient ischemic attack

1.80 (1.59-2.04)***

1.25 (1.08-1.46)**

Hyperlipidemia

1.27 (1.23-1.32)***

1.11 (1.06-1.15)***

SGA – second-generation antipsychotic, AD – antidepressant
a
adjusted for gender, age, psychiatric diagnosis and medical morbidity count,
*p <0.05, **p<0.01, ***p<0.0001

medication discontinuation. Each of these findings was confirmed and consistent even when age, gender, and medical
morbidity were taken into account.
The risk for stroke in subjects on SGAs has received substantial attention (22-38). Most, but not all, studies documented an increased risk for stroke in SGA users; however,
without exception, these studies included elderly subjects
(generally 65 years) (22-38), and most focused on patients
with dementia (22-38). To the best of our knowledge, the
present study is the first documentation of a clinically significant increase in stroke risk, as well as coronary artery disease risk, in a younger population (mean age544.46 years)
receiving SGAs. While increasing age, male gender and

medical morbidity also significantly contributed to the risk
for stroke and coronary artery disease, these additional risk
factors did not detract from the risk increase associated
with SGA exposure.
Our examination of long-term adverse outcomes by individual SGA or mixed SGA group has to be considered very
preliminary and interpreted with caution. Reasons for this
include the vastly different sample sizes of the individual
SGA groups, making it more likely to show a significant difference compared to AD users the larger the sample size
per subgroup was. In this context, it is notable that olanzapine (N52,901) and mixed SGAs (N53,997), which were
among the smallest groups, were also among the three
treatments with the highest number of adverse metabolic
and cardiovascular effects. Conversely, although aripiprazole (N57,316) was prescribed to the second highest number of patients, it was in the lower risk group, together with
risperidone (N53,362) and ziprasidone (N51,469), for
which power was much lower and may have been insufficient to detect a significant difference compared to AD users.
However, the non-random treatment assignment is an even
larger confounding factor. Clinician’s choice treatment with
SGAs is vulnerable to a channeling bias, i.e., the preferential
use of lower risk agents in higher risk patients and vice versa.
In any case, these data underscore the need to establish
which antipsychotics may possess lower short- and, particularly, long-term cardiovascular and cerebrovascular risk.
Such studies need to be sufficiently large and avoid or
control for channeling bias.
The strength of a healthcare claims database is the ability
to study large numbers of subjects who are not restricted to
those consenting to participate in research over a relatively
long duration of time. This may have allowed for our observation of increased cardiovascular and cerebrovascular risk
in this younger population, which may not be evident in
smaller clinical samples.

Table 5 Multivariable Cox hazard ratios for significant adverse outcomes of interest by SGA risk group

Outcome: claims
diagnosis

Hazard ratio
(95% CI)
for aripiprazole
(N57,316) vs. ADs

Stroke

0.95 (0.65-1.39)

1.60 (1.06-2.41)*

1.60 (1.26-2.01)***

1.71 (1.15-2.54)**

1.05 (0.54-2.05)

1.64 (1.16-2.32)**

Obesity

1.14 (1.01-1.28)*

0.80 (0.66-0.97)*

0.86 (0.78-0.94)**

0.86 (0.71-1.02)

1.08 (0.88-1.34)

1.09 (0.95-1.24)

Diabetes mellitus

1.22 (1.06-1.40)**

1.38 (1.16-1.60)**

1.36 (1.23-1.50)***

1.61 (1.37-1.89)***

1.78 (1.44-2.20)***

1.73 (1.51-1.98)***

Essential hypertension

1.00 (0.93-1.08)

1.17 (1.06-1.28)**

1.24 (1.18-1.31)***

1.05 (0.95-1.15)

1.25 (1.10-1.43)**

1.25 (1.15-1.35)***

Hazard ratio
(95% CI) for
olanzapine
(N52,901) vs. ADs

Hazard ratio
(95% CI)
for quetiapine
(N512,094) vs. ADs

Hazard ratio
(95% CI)
for risperidone
(N53,362) vs. ADs

Hazard ratio
(95% CI)
for ziprasidone
(N51,469) vs. ADs

Hazard ratio
(95% CI)
for mixed SGAs
(N53,997) vs. ADs

Hyperlipidemia

1.09 (1.01-1.19)*

1.20 (1.08-1.33)**

1.08 (1.02-1.15)*

1.01 (0.90-1.13)

1.27 (1.10-1.46)**

1.23 (1.12-1.35)***

Hypertensive heart disease

1.12 (0.76-1.66)

1.18 (0.72-1.93)

1.39 (1.07-1.81)*

0.90 (0.52-1.58)

1.74 (0.97-3.12)

1.92 (1.34-2.75)**

Angina

0.51 (0.34-0.77)**

1.05 (0.70-1.56)

1.24 (1.01-1.53)*

0.61 (0.36-1.02)

2.02 (1.34-3.05)**

1.09 (0.78-1.54)

Myocardial infarction

0.84 (0.51-1.41)

1.67 (1.04-2.68)*

1.15 (0.83-1.59)

0.63 (0.30-1.34)

0.40 (0.10-1.61)

1.03 (0.60-1.76)

Coronary artery disease

0.88 (0.70-1.11)

1.20 (0.94-1.55)

1.27 (1.10-1.46)*

1.03 (0.78-1.35)

1.36 (0.96-1.92)

1.30 (1.04-1.63)*

Transient ischemic attack

0.80 (0.56-1.14)

1.13 (0.75-1.71)

1.21 (0.97-1.51)

1.13 (0.75-1.71)

1.64 (1.02-2.61)*

1.47 (1.07-2.00)**

SGA – second-generation antipsychotic, ADs – antidepressants, *p <0.05, **p<0.01, ***p<0.0001
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Table 6 Incidence of events per 1000 person-years
SGA users (cases per
1,000 person-years)

AD users (cases per
1,000 person-years)

Essential hypertension

79.2

62.7

Diabetes mellitus

23.4

13.5

Obesity

23.2

18.5

Outcome

Stroke

3.7

1.8

Hypertensive heart disease

2.9

1.8

Myocardial infarction

1.7

1.2

Angina

4.0

3.0

Coronary artery disease

9.3

6.1

Transient ischemic attack

4.1

2.4

59.1

46.0

Hyperlipidemia

SGA – second-generation antipsychotic, AD – antidepressant

Nevertheless, database studies also have limitations.
These include the non-randomized treatment groups, naturalistic treatment setting and lack of information about unhealthy lifestyle behaviors, including smoking. In order to
reduce the effect of unhealthy lifestyle behaviors and other
background risk factors that we were unable to measure, we
used a psychiatric control group in an inception cohort
design, choosing AD use as our control. We made this choice
because both depression and ADs have been associated with
metabolic syndrome and its components as well as with distal
adverse cardiovascular and cerebrovascular outcomes (4042). However, since patients receiving SGAs and ADs may
differ in specific risk factors for the outcomes under investigation, we used covariates in the Cox regression analyses to
adjust for potentially relevant differences. Covariates included traditional risk factors, such as gender and age. In addition, we adjusted the analyses for a primary diagnosis of
schizophrenia or mood disorder as well as for a medical
comorbidity count. Notably, while each of these covariates
was significantly related to the outcomes of interest, the
higher risk in SGA users persisted even when adjusting for
these variables.
Another limitation is lacking information about the duration and severity of the current illness episode. However, to
mitigate against this problem, we used the inception cohort
design focusing on patients with illness severity prompting
clinicians to initiate treatment with an SGA or AD. Additionally, while the treatment was clinician and patient driven, the
naturalistic database approach ensures greater generalizability of the findings than in controlled trials, that ordinarily also have higher attrition rates.
Further, we did not have body mass index and laboratory data available, so that the diagnoses, particularly of
more proximal cardiometabolic risk factors and metabolic
outcomes, may be an underestimate. In this context, we
cannot fully rule out a surveillance bias in that SGA treated
patients may have had more measurements of body weight
and laboratory parameters than AD treated patients. How-

ever, although monitoring guidelines exist for SGAs (14,43),
they are notoriously seldom followed, and several studies
failed to observe any change in monitoring after the warning
about metabolic effects of SGAs by the FDA and guideline
development and promulgation (44). Nevertheless, even if a
surveillance bias may have led to a greater detection of cardiovascular risk factors and metabolic outcomes, the cardiovascular and cerebrovascular outcomes are much less dependent on detection bias and diagnoses are not made by
laboratory testing, which strengthens our results.
A further limitation is that data were only available from
2006 to 2010, and that 2006 through the first date of SGA
or AD exposure was used as a “baseline period”. Therefore,
we do not have any details of medical history on subjects
included in our study prior to 2006. We used an absence of
drug claims for SGAs and ADs in 2006 as a proxy for no
past SGA and AD use. Although it is possible that our study
subjects could have used SGAs prior to 2006, this fact would
only bias towards the null hypothesis, as the AD group could
have had carry over effects from prior SGA use. Further,
although we “only” had a 2-year median follow-up, even this
still relatively short observation period was sufficient to demonstrate significant elevations of risk for both proximal and
more distal cardiovascular and cerebrovascular risk factors
and endpoints, which adds to the concern regarding the widespread use of SGAs, especially for off-label conditions (8,9).
Cigarette smoking is a risk factor for both cardiovascular
and cerebrovascular disease. It is also more common in
people with a psychiatric diagnosis and who are on psychotropic medicines (45). Moreover, smoking rates are generally
reported to be higher in schizophrenia than in subjects with
mood disorders (46). Our database did not allow us to obtain
smoking information by subject, so that the effect of cigarette
smoking as a confounding factor cannot be definitively excluded. However, the fact that the risk for SGAs versus ADs
held even when the diagnoses of schizophrenia and mood disorders were entered as covariates into the analyses, strengthens our results as not likely being attributable to a differential
frequency of cigarette smoking.
In the U.S., increased use of SGAs over the last 20 years
has been clearly documented (8,39). SGAs are effective for
psychotic and mood disorders (4-7); however, they are also
widely used for numerous off-label conditions (8,9,39), and
an ever-increasing number of patients is being prescribed
this class of psychotropic agents without appropriate monitoring (44). Our data suggest that the risks associated with
SGA use extend beyond the adverse metabolic risks that are
well-known (10-18). It is highly likely that the increased risk
for major cerebrovascular and cardiovascular events we observed is a downstream consequence of these well-documented
metabolic risks (13,15). Greater care should be exercised in
monitoring and mitigating the adverse metabolic consequences of SGAs, even in a younger population, and these
medications should be used with greater caution, especially
in conditions for which a sufficient evidence base for efficacy and safety is missing.
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